Kodiak Sciences Surges 162% on Successful Phase III Eye Drug Trials

Key Facts

1Kodiak Sciences shares surged over 162% after Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK trial.

Kodiak Sciences shares surged over 162% after Zenkuda and tabirafusp-ted met primary endpoints in the Phase III DAYBREAK trial. Reuters reported that the experimental drugs demonstrated noninferiority to aflibercept in vision gains at one year, positioning them as potential competitors in the treatment of wet age-related macular degeneration.

KOD closed at $32.35 on September 25, 2026, prior to the clinical announcement that triggered the massive rally. The company stated it plans to submit a biologics license application for Zenkuda in the fourth quarter of 2026, following successful pivotal studies across multiple conditions including diabetic retinopathy and macular edema.